Suppr超能文献

人源Pin1的高亲和力肽抑制的结构基础

Structural basis for high-affinity peptide inhibition of human Pin1.

作者信息

Zhang Yan, Daum Sebastian, Wildemann Dirk, Zhou Xiao Zhen, Verdecia Mark A, Bowman Marianne E, Lücke Christian, Hunter Tony, Lu Kun-Ping, Fischer Gunter, Noel Joseph P

机构信息

The Jack H. Skirball Center for Chemical Biology and Proteomics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.

出版信息

ACS Chem Biol. 2007 May 22;2(5):320-8. doi: 10.1021/cb7000044.

Abstract

Human Pin1 is a key regulator of cell-cycle progression and plays growth-promoting roles in human cancers. High-affinity inhibitors of Pin1 may provide a unique opportunity for disrupting oncogenic pathways. Here we report two high-resolution X-ray crystal structures of human Pin1 bound to non-natural peptide inhibitors. The structures of the bound high-affinity peptides identify a type-I beta-turn conformation for Pin1 prolyl peptide isomerase domain-peptide binding and an extensive molecular interface for high-affinity recognition. Moreover, these structures suggest chemical elements that may further improve the affinity and pharmacological properties of future peptide-based Pin inhibitors. Finally, an intramolecular hydrogen bond observed in both peptide complexes mimics the cyclic conformation of FK506 and rapamycin. Both FK506 and rapamycin are clinically important inhibitors of other peptidyl-prolyl cis-trans isomerases. This comparative discovery suggests that a cyclic peptide polyketide bridge, like that found in FK506 and rapamycin or a similar linkage, may significantly improve the binding affinity of structure-based Pin1 inhibitors.

摘要

人源Pin1是细胞周期进程的关键调节因子,在人类癌症中发挥促生长作用。Pin1的高亲和力抑制剂可能为破坏致癌途径提供独特的机会。在此,我们报告了人源Pin1与非天然肽抑制剂结合的两个高分辨率X射线晶体结构。结合的高亲和力肽的结构确定了Pin1脯氨酰肽异构酶结构域与肽结合的I型β-转角构象以及高亲和力识别的广泛分子界面。此外,这些结构提示了可能进一步改善未来基于肽的Pin抑制剂亲和力和药理特性的化学元素。最后,在两种肽复合物中观察到的分子内氢键模拟了FK506和雷帕霉素的环状构象。FK506和雷帕霉素都是临床上重要的其他肽基脯氨酰顺反异构酶抑制剂。这一比较发现表明,类似于FK506和雷帕霉素中发现的环状肽聚酮桥或类似的连接方式,可能会显著提高基于结构的Pin1抑制剂的结合亲和力。

相似文献

1
Structural basis for high-affinity peptide inhibition of human Pin1.
ACS Chem Biol. 2007 May 22;2(5):320-8. doi: 10.1021/cb7000044.
2
Discovery and characterization of a nonphosphorylated cyclic peptide inhibitor of the peptidylprolyl isomerase, Pin1.
J Med Chem. 2011 Jun 9;54(11):3854-65. doi: 10.1021/jm200156c. Epub 2011 May 5.
3
Substrate-based design of reversible Pin1 inhibitors.
Biochemistry. 2002 Oct 1;41(39):11868-77. doi: 10.1021/bi0262395.
5
Structure-based design of novel human Pin1 inhibitors (I).
Bioorg Med Chem Lett. 2009 Oct 1;19(19):5613-6. doi: 10.1016/j.bmcl.2009.08.034. Epub 2009 Aug 13.
6
Structure-based design of novel human Pin1 inhibitors (II).
Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. doi: 10.1016/j.bmcl.2010.02.033. Epub 2010 Feb 14.
7
Membrane permeable cyclic peptidyl inhibitors against human Peptidylprolyl Isomerase Pin1.
J Med Chem. 2010 Mar 25;53(6):2494-501. doi: 10.1021/jm901778v.
8
A reduced-amide inhibitor of Pin1 binds in a conformation resembling a twisted-amide transition state.
Biochemistry. 2011 Nov 8;50(44):9545-50. doi: 10.1021/bi201055c. Epub 2011 Oct 18.
9
Thermodynamics of phosphopeptide binding to the human peptidyl prolyl cis/trans isomerase Pin1.
Biochemistry. 2006 Oct 3;45(39):12125-35. doi: 10.1021/bi0608820.
10
Structure-guided design of alpha-amino acid-derived Pin1 inhibitors.
Bioorg Med Chem Lett. 2010 Jan 15;20(2):586-90. doi: 10.1016/j.bmcl.2009.11.090. Epub 2009 Nov 22.

引用本文的文献

1
Pin1 WW Domain Ligand Library Synthesized with an Easy Solid-Phase Phosphorylating Reagent.
Biochemistry. 2024 Nov 5;63(21):2803-2815. doi: 10.1021/acs.biochem.4c00231. Epub 2024 Oct 8.
4
The role of the master cancer regulator Pin1 in the development and treatment of cancer.
Front Cell Dev Biol. 2024 Apr 30;12:1343938. doi: 10.3389/fcell.2024.1343938. eCollection 2024.
6
Dissecting the Allosteric Fine-Tuning of Enzyme Catalysis.
JACS Au. 2024 Feb 6;4(2):837-846. doi: 10.1021/jacsau.3c00806. eCollection 2024 Feb 26.
8
Proline Isomerization: From the Chemistry and Biology to Therapeutic Opportunities.
Biology (Basel). 2023 Jul 14;12(7):1008. doi: 10.3390/biology12071008.
9
Small molecules targeting Pin1 as potent anticancer drugs.
Front Pharmacol. 2023 Mar 27;14:1073037. doi: 10.3389/fphar.2023.1073037. eCollection 2023.
10
Regulation of eukaryotic protein kinases by Pin1, a peptidyl-prolyl isomerase.
Adv Biol Regul. 2023 Jan;87:100938. doi: 10.1016/j.jbior.2022.100938. Epub 2022 Nov 30.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
3
Pin1 flips Alzheimer's switch.
ACS Chem Biol. 2006 May 23;1(4):214-6. doi: 10.1021/cb600171g.
4
Targeting carcinogenesis: a role for the prolyl isomerase Pin1?
Mol Carcinog. 2006 Jun;45(6):397-402. doi: 10.1002/mc.20216.
5
Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases.
Handb Exp Pharmacol. 2006(172):359-404. doi: 10.1007/3-540-29717-0_15.
8
Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer.
Clin Cancer Res. 2005 Oct 15;11(20):7523-31. doi: 10.1158/1078-0432.CCR-05-0457.
9
Pin1 overexpression in colorectal cancer and its correlation with aberrant beta-catenin expression.
World J Gastroenterol. 2005 Aug 28;11(32):5006-9. doi: 10.3748/wjg.v11.i32.5006.
10
Phosphorylation-specific prolyl isomerization: is there an underlying theme?
Nat Cell Biol. 2005 May;7(5):435-41. doi: 10.1038/ncb0505-435.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验